Citigroup
ABEO icon

Citigroup’s Abeona Therapeutics ABEO Stock Holding History

Citigroup’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-200
Closed -$11K – 7508
2020
Q1 		$11K Sell
200
-380
-66% -$25.4K ﹤0.01% 6994
2019
Q4 		$47K Sell
580
-156
-21% -$11K ﹤0.01% 6345
2019
Q3 		$42K Sell
736
-116
-14% -$8.69K ﹤0.01% 6227
2019
Q2 		$102K Buy
852
+504
+145% +$84.5K ﹤0.01% 5856
2019
Q1 		$64K Buy
348
+336
+2,800% +$60.1K ﹤0.01% 6128
2018
Q4 		$2K Sell
12
-276
-96% -$60.2K ﹤0.01% 7488
2018
Q3 		$92K Buy
288
+160
+125% +$56.8K ﹤0.01% 5983
2018
Q2 		$51K Buy
+128
New +$55.9K ﹤0.01% 6267

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup's ABEO Position: Q1 2026 in Review

Citigroup increased its Abeona Therapeutics (ABEO) stake by 0.26% in Q1 2026, buying an estimated $6.79K and bringing the position to 522,445 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2572.

Citigroup first reported a position in ABEO in Q2 2015 and has held it in 36 quarters since. The position peaked at $3.9M in Q3 2024. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Citigroup held 522,445 shares of Abeona Therapeutics worth $2.34M as of Q1 2026.
  • Citigroup bought 1,358 Abeona Therapeutics shares in Q1 2026, an estimated $6.79K.
  • Abeona Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2572 holding.
  • Citigroup first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 36 quarters since.
  • Citigroup's Abeona Therapeutics position peaked at $3.9M in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.